Sangamo Therapeutics, Inc.
SGMOQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$884.7M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $884.70 Million |
|---|---|
| Enterprise Value | $884.69 Million |
| Earnings per Share | $- |
| Beta | 1.4 |
| Outstanding Shares | - |
Return
| Return on Equity | -468187.69% |
|---|---|
| Return on Assets | -85789.41% |
| Return on Invested Capital | -87410.88% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 25.6 |
| Enterprise Value to EBIT | -7.04 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 28, 2026
EPS Estimate
$0.01
Consensus analyst estimateRevenue Estimate
$33.73 M
Consensus analyst estimateNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
$500,000
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Sangamo Therapeutics Inc
142 employees
CEO: Alexander Macrae
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous syste...